Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
about
Aripiprazole: from pharmacological profile to clinical useEfficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trialsReview of depot aripiprazole for schizophreniaWhen to start aripiprazole therapy in patients with bipolar maniaUpdate on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor AntagonismBrexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazoleAripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration.Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled StudyDrug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.Towards a framework for treatment effectiveness in schizophrenia.Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis.Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trialsHospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysisUse of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia.Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia.Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia.Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysisOptimizing outcomes in schizophrenia: long-acting depots and long-term treatment.Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection.Weight gain and antipsychotics: a drug safety review.Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.Treatment of adult patients with schizophrenia and complex mental health needs - A national clinical guideline.Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.The Use of Long-Acting Injectable Antipsychotics in Schizophrenia.Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole.Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly.Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
P2860
Q26778312-2A0FB306-441B-4C49-9CF9-FFD6F4862D5AQ26781173-F73139A8-420C-4AD1-B032-4835A236B117Q27008464-F84BE864-05E1-40B3-8461-1AD2860497DBQ27014860-8A2264FE-A93C-4899-A59B-6E5199BCAAECQ28084069-C3A7DCD2-9BA8-4EEB-8504-DF22A62E7659Q28468613-BCED1C26-71A3-4B8D-A78A-C10CF7941D4AQ33614458-9F488613-ACE2-4A20-8721-2F05AC4C6E6CQ33625354-8C62B6BF-EC65-4D1E-BF30-7290794C7A39Q33650097-35F38FD9-FB41-417F-99E3-EC365754F917Q33802918-C928B6C5-9980-4582-8A6D-FD2696A3201EQ34274631-826F4C12-5528-468D-A95A-CC6599155496Q34322714-9F489813-58EA-4C14-AC9F-7A1BCD5F9BE9Q34325164-F1A0B346-0D6C-48E5-B7E7-2EE625E64171Q34501911-93F10D6A-5437-40E3-A23D-7D9603A0DDDCQ34775426-16CE2188-BFEC-4B85-ADDE-12DC5D0FC294Q35683821-52334D16-0AB1-4D5D-9E73-F9F92921D5BAQ36001512-7BF1F944-8817-4ED0-802A-73360455807CQ36550998-8666A3C3-9113-42FD-95EE-CC4C8008EC9BQ36627644-64A3DFED-F48B-4E9F-9299-7900161E873CQ36798150-DFE5709E-F04A-45D2-8C9C-B61F12F5A123Q37007725-91C69435-C6BA-4225-A39F-6660D697F2DAQ37280123-B5C70173-ADFF-4310-BFAE-B23C2D88E0E3Q38086645-B4571214-AF94-4763-B07B-D90CF5290EC7Q38115487-06A7C3D2-C9A5-4DBE-B412-20AE94D8C051Q38125213-9590EB17-5C52-4538-AF64-E0D4F5DF65ECQ38223569-BD1783DD-A80B-4BB9-916B-3286E63B2283Q38248274-B2E7E050-9DB1-4041-8BB8-ADCD16F3B4ABQ38268590-BD68EDD6-95F0-43A8-8925-68C9B281843CQ38271353-9151D910-66C4-4FE4-A37B-F0B9E4CE10D1Q38570636-D3AE521A-02F7-48A0-B035-4EF1405A2065Q38578316-EF3B74E4-3CDF-493E-A74A-96D7DF7E3D90Q38649630-5A461824-8922-4964-B442-F98A0B282E4EQ38692993-15389A89-3B22-4F76-A8B6-E4101FFDE67CQ38728652-3E75D702-EB10-4380-AFF5-A512EE734939Q38744570-4E8976D4-4BE0-4F8F-A3F8-9FB371BE3C64Q38810111-1827F6C9-5BD2-4542-BEB2-C1F138DA24DAQ38851123-7D2D9A0F-B21B-421B-910B-053121C06688Q38851847-743BBE57-091C-48FF-902B-53715B16BF9DQ38989642-D0CFB95B-F57E-4A99-81D0-99D4634E4EABQ39065466-EBE0711A-B9CD-4A96-9A60-AED07400A3F9
P2860
Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Aripiprazole intramuscular dep ...... ind, placebo-controlled study.
@en
type
label
Aripiprazole intramuscular dep ...... ind, placebo-controlled study.
@en
prefLabel
Aripiprazole intramuscular dep ...... ind, placebo-controlled study.
@en
P2093
P921
P356
P1476
Aripiprazole intramuscular dep ...... ind, placebo-controlled study.
@en
P2093
Brian R Johnson
John M Kane
Pamela P Perry
Raymond Sanchez
Robert A Forbes
Robert D McQuade
W Wolfgang Fleischhacker
William H Carson
P304
P356
10.4088/JCP.11M07530
P577
2012-05-01T00:00:00Z